New drug combo aims to shrink tumors before lung cancer surgery
NCT ID NCT05775796
Summary
This study tested whether adding the immunotherapy drug serplulimab to standard chemotherapy, given both before and after surgery, could help people with operable non-small cell lung cancer. The goal was to see if this combination could shrink tumors more effectively before surgery and prevent the cancer from coming back afterward. Researchers enrolled 30 patients to measure how well the treatment worked and how safe it was.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON-SMALL CELL LUNG CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Fudan University Shanghai Cancer Center
Shanghai, Shanghai Municipality, 200032, China
Conditions
Explore the condition pages connected to this study.